Literature DB >> 28228086

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Pavlos Msaouel1, Mateusz Opyrchal2, Angela Dispenzieri3,4, Kah Whye Peng4, Mark J Federspiel4, Stephen J Russell3,4, Evanthia Galanis4,5.   

Abstract

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer gene therapy; MV-CEA; MV-NIS; measles virus clinical trials; oncolytic measles; virotherapy

Mesh：

Year:  2018        PMID： 28228086      PMCID： PMC5630504          DOI： 10.2174/1568009617666170222125035

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  86 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells.

Authors:  Lucie Heinzerling; Valerie Künzi; Patrick A Oberholzer; Thomas Kündig; Hussein Naim; Reinhard Dummer
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

3.  Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy.

Authors:  M Opyrchal; C Allen; P Msaouel; I Iankov; E Galanis
Journal:  Cancer Gene Ther       Date:  2013-10-25       Impact factor: 5.987

4.  Rescue and propagation of fully retargeted oncolytic measles viruses.

Authors:  Takafumi Nakamura; Kah-Whye Peng; Mary Harvey; Suzanne Greiner; Ian A J Lorimer; Charles D James; Stephen J Russell
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

Review 5.  Use of attenuated paramyxoviruses for cancer therapy.

Authors:  Patrycja J Lech; Stephen J Russell
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

Review 6.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

7.  MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.

Authors:  Hirosha Geekiyanage; Evanthia Galanis
Journal:  Mol Oncol       Date:  2016-07-28       Impact factor: 6.603

8.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

9.  Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.

Authors:  Anne Gauvrit; Samantha Brandler; Carole Sapede-Peroz; Nicolas Boisgerault; Frédéric Tangy; Marc Gregoire
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.

Authors:  I D Iankov; C B Kurokawa; A B D'Assoro; J N Ingle; E Domingo-Musibay; C Allen; C M Crosby; A A Nair; M C Liu; I Aderca; M J Federspiel; E Galanis
Journal:  Cancer Gene Ther       Date:  2015-08-14       Impact factor: 5.987
View more
  47 in total

Review 1.  From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.

Authors:  Julijan Kabiljo; Johannes Laengle; Michael Bergmann
Journal:  Cell Death Discov       Date:  2020-06-11

Review 2.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

Review 3.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 4.  Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Authors:  Robin A Buerki; Zinal S Chheda; Hideho Okada
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

5.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 6.  The emerging role of oncolytic virus therapy against cancer.

Authors:  Luke Russell; Kah-Whye Peng
Journal:  Chin Clin Oncol       Date:  2018-04

7.  Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.

Authors:  Sarah Aref; Anna Z Castleton; Katharine Bailey; Richard Burt; Aditi Dey; Daniel Leongamornlert; Rachel J Mitchell; Dina Okasha; Adele K Fielding
Journal:  Mol Ther       Date:  2020-02-04       Impact factor: 11.454

8.  Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Authors:  Yang Su; Yue Liu; Christopher R Behrens; Scott Bidlingmaier; Nam-Kyung Lee; Rahul Aggarwal; Daniel W Sherbenou; Alma L Burlingame; Byron C Hann; Jeffry P Simko; Gayatri Premasekharan; Pamela L Paris; Marc A Shuman; Youngho Seo; Eric J Small; Bin Liu
Journal:  JCI Insight       Date:  2018-09-06

9.  Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.

Authors:  Eugene S Bah; Rebecca A Nace; Kah Whye Peng; Miguel Ángel Muñoz-Alía; Stephen J Russell
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

Review 10.  Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.

Authors:  Norihiro Watanabe; Mary Kathryn McKenna; Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.